Last mentioned: Feb 26, 2026
QLE Spin-off Completion
Formal separation of the Quantum Leap Energy subsidiary into a standalone entity.
Commercial Ramp-up
Full-scale commercial production across medical and industrial isotope lines.
Silicon-28 Shipments
Initial shipments of high-purity Silicon-28 to semiconductor partners.
ASP Isotopes CEO Paul Mann announced a 2026 commercialization ramp-up, highlighted by the upcoming shipment of Silicon-28 and the strategic spin-off of its Quantum Leap Energy (QLE) subsidiary. The move signals a transition from a pre-commercial advanced materials firm to a revenue-generating producer of medical and industrial isotopes.
This page surfaces every story mentioning Quantum Leap Energy (QLE) across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Quantum Leap Energy (QLE) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |